1
|
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M. Corrigendum to "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 31 (2020) 17-29]. Ann Oncol 2023; 34:325. [PMID: 36529567 DOI: 10.1016/j.annonc.2022.11.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Affiliation(s)
- E Zucca
- Division of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern; Institute of Oncology Research, Bellinzona, Switzerland
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - C Buske
- Comprehensive Cancer Centre, University Hospital of Ulm, Ulm, Germany
| | - P W Johnson
- Cancer Research UK Centre, Southampton General Hospital, Southampton, UK
| | - M Ponzoni
- Vita-Salute San Raffaele University and Pathology Unit, San Raffaele Scientific Institute, Milan, Italy
| | - M Raderer
- Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria
| | - U Ricardi
- Department of Oncology, University of Turin, Turin, Italy
| | - A Salar
- Department of Hematology, Hospital del Mar, Barcelona, Barcelona, Spain
| | - K Stamatopoulos
- Institute of Applied Biosciences, CERTH, the Centre for Research and Technology Hellas, Thessaloniki, Greece
| | - C Thieblemont
- Department of Hematology, APHP-Saint-Louis Hospital, University Paris-Diderot, Paris, France
| | - A Wotherspoon
- Department of Histopathology, The Royal Marsden Hospital, London, UK
| | - M Ladetto
- Division of Hematology, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | | |
Collapse
|
2
|
Bachy E, Le Gouill S, Sesques P, Di Blasi R, Guillaume M, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Castilla Llorente C, Choquet S, Casasnovas RO, Mothy M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Zerbit J, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000843932.28141.4d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 2022; 33:259-275. [PMID: 34923107 DOI: 10.1016/j.annonc.2021.12.003] [Citation(s) in RCA: 125] [Impact Index Per Article: 62.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Accepted: 12/06/2021] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. DESIGN The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field. RESULTS Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues. CONCLUSIONS We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic.
Collapse
Affiliation(s)
- P J Hayden
- Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland
| | - C Roddie
- UCL Cancer Institute, London, UK; University College London Hospital NHS Foundation Trust, London, UK.
| | - P Bader
- Clinic for Children and Adolescents, University Children's Hospital, Frankfurt, Germany
| | - G W Basak
- Medical University of Warsaw, Department of Hematology, Transplantation and Internal Medicine, Warsaw, Poland
| | - H Bonig
- Institute for Transfusion Medicine and Immunohematology of Goethe University and German Red Cross Blood Service, Frankfurt, Germany
| | - C Bonini
- Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy
| | - C Chabannon
- Aix-Marseille université, Inserm CBT-1409, Institut Paoli-Calmettes, centre de thérapie cellulaire, unité de transplantation et de thérapie cellulaire, département de biologie du cancer, Marseille, France
| | - F Ciceri
- Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - S Corbacioglu
- Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Franz-Josef-Strauss-Allee 11, University Hospital of Regensburg, Regensburg, Germany
| | - R Ellard
- Royal Marsden Hospital, Fulham Rd, London, UK
| | - F Sanchez-Guijo
- IBSAL-Hospital Universitario de Salamanca, CIC, Universidad de Salamanca, Salamanca, Spain
| | - U Jäger
- Clinical Department for Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - M Hildebrandt
- Department of Transfusion Medicine, Cell Therapeutics and Haemostaseology, LMU University Hospital Grosshadern, Munich
| | - M Hudecek
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
| | - M J Kersten
- Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, Amsterdam, the Netherlands
| | - U Köhl
- Fraunhofer Institute for Cell Therapy and Immunology (IZI) and Institute of Clinical Immunology, University of Leipzig, Leipzig, Germany; Institute of Cellular Therapeutics, Hannover Medical School, Hannover, Germany
| | - J Kuball
- Department of Hematology and Centre for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - S Mielke
- Karolinska Institutet and University Hospital, Department of Laboratory Medicine/Department of Cell Therapy and Allogeneic Stem Cell Transplantation (CAST), Stockholm, Sweden
| | - M Mohty
- Hôpital Saint-Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France
| | - J Murray
- Christie Hospital NHS Trust, Manchester, UK
| | - A Nagler
- The Chaim Sheba Medical Center, Tel-Hashomer, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - J Rees
- University College London Hospital NHS Foundation Trust, London, UK; UCL Institute of Neurology, University College of London Hospitals NHS Foundation Trust, London, UK
| | - C Rioufol
- Hospices Civils de Lyon, UCBL1, EMR 3738 CICLY, Lyon, France
| | - R Saccardi
- Cell Therapy and Transfusion Medicine Department, Careggi University Hospital, Florence, Italy
| | - J A Snowden
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - J Styczynski
- Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland
| | - M Subklewe
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - C Thieblemont
- AP-HP, Saint-Louis Hospital, Hemato-oncology, University of Paris, Paris, France
| | - M Topp
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
| | - Á U Ispizua
- Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Barcelona, Spain
| | - D Chen
- University College London Hospital NHS Foundation Trust, London, UK; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - R Vrhovac
- Department of Haematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | - J G Gribben
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - N Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg, Germany
| | - H Einsele
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
| | - I Yakoub-Agha
- CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France
| |
Collapse
|
4
|
Bologna S, Vander Borght T, Briere J, Ribrag V, Damaj GL, Thieblemont C, Feugier P, Peyrade F, Lebras L, Coso D, Sibon D, Bonnet C, Morschhauser F, Ghesquieres H, Becker S, Olivier P, Fabiani B, Tilly H, Haioun C, Bastie JN. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.5_2879] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S Bologna
- Hématologie Privée Nancéienne 54 Essey lès Nancy France
| | | | - J Briere
- CHU Henri Mondor 94 Créteil France
| | - V Ribrag
- Institut Gustave Roussy 94 Villejuif France
| | | | | | - P Feugier
- CHRU Nancy 54 Vandoeuvre lès Nancy France
| | - F Peyrade
- Centre Antoine Lacassagne 06 Nice France
| | - L Lebras
- Centre Léon Berard 69 Lyon, France
| | - D Coso
- Institut Paoli Calmette 13 Marseille France
| | - D Sibon
- Hôpital Necker-Enfants Malades 75 Paris France
| | | | | | | | - S Becker
- Centre Henri Becquerel 76 Rouen France
| | - P Olivier
- CHRU Nancy 54 Vandoeuvre lès Nancy France
| | - B Fabiani
- Hopital Saint Antoine 75 Paris France
| | - H Tilly
- Centre Henry Becquerel 76 Rouen France
| | - C Haioun
- Hopital Henri Mondor 94 Créteil France
| | | |
Collapse
|
5
|
Schuster SJ, Dickinson M, Dreyling M, Martinez‐Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Abdelhady A, Zia A, Morisse MC, Fowler NH, Thieblemont C. EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA‐CEL) IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.85_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. J. Schuster
- Perelman Center for Advanced Medicine University of Pennsylvania Philadelphia USA
| | - M. Dickinson
- Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Australia
| | - M. Dreyling
- Medizinische Klinik III, LMU Klinikum Munich Germany
| | - J. Martinez‐Lopez
- Hospital 12 De Octubre Madrid Complutense University CNIO Madrid Spain
| | - A. Kolstad
- Department of Oncology Oslo University Hospital Oslo Norway
| | - J. Butler
- Haematology and Bone Marrow Transplantation Royal Brisbane Hospital Herston Australia
| | - M. Ghosh
- Department of Internal Medicine Michigan Medicine University of Michigan Ann Arbor USA
| | - L. Popplewell
- Department of Hematology & Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte USA
| | - J. C. Chavez
- Department of Malignant Hematology Moffitt Cancer Center Tampa USA
| | - E. Bachy
- Department of Hematology Hospices Civils de Lyon and Université Claude Bernard Lyon 1 Lyon France
| | - K. Kato
- Department of Hematology Kyushu University Hospital Fukuoka Japan
| | - H. Harigae
- Department of Hematology Tohoku University Hospital Sendai Japan
| | - M. José Kersten
- Cancer Center Amsterdam Amsterdam UMC University of Amsterdam on behalf of HOVON/LLPC Amsterdam Netherlands
| | - C. Andreadis
- Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco USA
| | - P. A. Riedell
- Department of Medicine University of Chicago Chicago USA
| | - A. Abdelhady
- Oncology Novartis Pharmaceuticals Corporation East Hanover USA
| | - A. Zia
- Biostatistics Novartis Pharma AG Basel Switzerland
| | - M. C. Morisse
- Oncology Novartis Pharmaceuticals Corporation East Hanover USA
| | - N. H. Fowler
- MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center Houston Texas USA
| | - C. Thieblemont
- Department of Hemato‐Oncology Hôpital Saint‐Louis‐Université de Paris Paris France
| |
Collapse
|
6
|
Gouill S, Bachy E, Blasi R, Cartron G, Beauvais D, Bras F, Gros F, Choquet S, Bories P, Rubio M, Casasnovas R, Bounaix L, Mohty M, Joris M, Gastinne T, Sesques P, Tudesq JJ, Morschhauser F, Gat E, Broussais F, Thieblemont C, Houot R. FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES. Hematol Oncol 2021. [DOI: 10.1002/hon.84_2879] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. Gouill
- CHU de Nantes Hematology Nantes France
| | | | - R. Blasi
- Höpital Saint‐Louis APHP Hematology PAris France
| | - G. Cartron
- CHU de Montpellier Hematology Montpellier France
| | | | - F. Bras
- CHU Creteil Hematology Creteil France
| | | | - S. Choquet
- Hôpital La Pitié‐Salpetrière ‐ APHP Hematology Paris France
| | - P. Bories
- Oncopole de Toulouse Hematology Toulouse France
| | | | | | - L. Bounaix
- CHU de Clermont‐Ferrand Hematology Clermont‐Ferrand France
| | - M. Mohty
- Hôpital Saint‐Antoine Hematology Paris France
| | - M. Joris
- CHU Amiens Hematology Amiens France
| | | | | | - J. J. Tudesq
- CHU de Montpellier Hematology Montpellier France
| | | | - E. Gat
- LYSARC DESCAR‐T LYON France
| | | | | | - R. Houot
- CHU de Rennes Hematology Rennes France
| |
Collapse
|
7
|
Fowler NH, Dickinson M, Martinez‐Lopez J, Kolstad A, Schuster SJ, Dreyling M, Ghosh M, Harigae H, Kersten MJ, Bachy E, Popplewell L, Chavez JC, Ho PJ, Butler J, Kato K, Tresckow B, Ferreri AJM, Simón JAP, Patten PEM, Andreadis C, Riedell PA, McGuirk JP, Nastoupil LJ, Teshima T, Offner F, Petzer A, Viardot A, Zinzani PL, Malladi R, Zhang J, Tiwari R, Bollu V, Masood A, Thieblemont C. PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL). Hematol Oncol 2021. [DOI: 10.1002/hon.178_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- N. H. Fowler
- The University of Texas MD Anderson Cancer Center Department of Lymphoma‐Myeloma Houston Texas USA
| | - M. Dickinson
- Royal Melbourne Hospital Peter MacCallum Cancer Centre Melbourne Australia
| | | | - A. Kolstad
- Oslo University Hospital Department of Oncology Oslo Norway
| | - S. J. Schuster
- University of Pennsylvania Lymphoma Program Philadelphia Pennsylvania USA
| | - M. Dreyling
- LMU Klinikum Medizinische Klinik III Munich Germany
| | - M. Ghosh
- University of Michigan Michigan Medicine Ann Arbor Michigan USA
| | - H. Harigae
- Tohoku University Hospital Department of Hematology and Rheumatology Sendai Japan
| | - M. José Kersten
- Amsterdam UMC University of Amsterdam on behalf of HOVON/LLPC Department of Hematology Amsterdam Netherlands
| | - E. Bachy
- Université Claude Bernard Lyon 1 Hospices Civils de Lyon Lyon France
| | - L. Popplewell
- City of Hope National Medical Center Department of Hematology & Hematopoietic Cell Transplantation Duarte California USA
| | - J. C. Chavez
- Moffitt Cancer Center Department of Malignant Hematology Tampa Florida USA
| | - P. J. Ho
- Royal Prince Alfred Hospital and University of Sydney Institute of Haematology Camperdown Australia
| | - J. Butler
- Royal Brisbane Hospital Haematology and Bone Marrow Transplant Unit Herston Australia
| | - K. Kato
- Kyushu University Hospital Hematology, Oncology, & Cardiovascular Medicine Fukuoka Japan
| | - B. Tresckow
- University Hospital Essen University of Duisburg‐Essen Clinic for Hematology and Stem Cell Transplantation West German Cancer Center Essen Germany
| | - A. J. M. Ferreri
- IRCCS Ospedale San Raffaele Department of Onco‐hematology Milan Italy
| | - J. A. P. Simón
- University Hospital Virgen del Rocío Instituto de Biomedicina de Sevilla (IBIS / CSIC / CIBERONC) Universidad de Sevilla Department of Hematology Sevilla Spain
| | - P. E. M. Patten
- King’s College Hospital and King’s College London Division of Cancer Studies London UK
| | - C. Andreadis
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco California USA
| | - P. A. Riedell
- University of Chicago Medical Center Department of Medicine Chicago Illinois USA
| | - J. P. McGuirk
- University of Kansas Medical Center Division of Hematologic Malignancies and Cellular Therapeutics Kansas City Kansas USA
| | - L. J. Nastoupil
- The University of Texas MD Anderson Cancer Center Department of Lymphoma‐Myeloma Houston Texas USA
| | - T. Teshima
- Hokkaido University Hospital Department of Hematology Sapporo Japan
| | - F. Offner
- UZ Gent Department of Hematology Gent Belgium
| | - A. Petzer
- Ordensklinikum Linz GmbH Elisabethinen Internal Medicine I Linz Austria
| | - A. Viardot
- University Hospital of Ulm Department of Internal Medicine III Ulm Germany
| | - P. L. Zinzani
- University of Bologna Institute of Hematology “Seràgnoli” Bologna Italy
| | - R. Malladi
- Cambridge University Hospitals NHS Foundation Trust Centre for Clinical Haematology Cambridge UK
| | - J. Zhang
- Novartis Pharmaceuticals Corporation Global Value and Access East Hanover New Jersey USA
| | - R. Tiwari
- Novartis Healthcare Pvt. Ltd Biostatistics Hyderabad India
| | - V. Bollu
- Novartis Pharmaceuticals Corporation Health Economics and Outcomes Research East Hanover New Jersey USA
| | - A. Masood
- Novartis Pharmaceuticals Corporation Clinical Development East Hanover New Jersey USA
| | - C. Thieblemont
- Hôpital Saint‐Louis‐Université de Paris Service d'Hématologie‐Oncologie Paris France
| |
Collapse
|
8
|
Trotman J, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj‐Teague M, Zinzani PL, Coleman M, Browett P, Ke X, Sun M, Marcus R, Portell C, Thieblemont C, Zhou K, Liberati AM, Bachy E, Cavallo F, Costello R, Iyengar S, Marasca R, Mociková H, Kim JS, Talaulikar D, Co M, Zhou W, Huang J, Opat S. SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY). Hematol Oncol 2021. [DOI: 10.1002/hon.19_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Trotman
- Concord Repatriation General Hospital University of Sydney Oncology Concord Australia
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - K. Linton
- The Christie Hematology Manchester UK
| | - P. McKay
- Beatson West of Scotland Cancer Centre Oncology Glasgow UK
| | - B. Hu
- Levine Cancer Institute/Atrium Health Oncology Charlotte USA
| | - H. Chan
- North Shore Hospital Haematology Auckland New Zealand
| | - J. Jin
- The First Affiliated Hospital Zhejiang University Hematology Hangzhou China
| | | | - P. L. Zinzani
- Institute of Hematology “Seràgnoli” University of Bologna Hematology Bologna Italy
| | - M. Coleman
- Clinical Research Alliance Hematology Lake Success USA
| | - P. Browett
- Auckland City Hospital Haematology Grafton New Zealand
| | - X. Ke
- Peking University Third Hospital Hematology Beijing China
| | - M. Sun
- Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences Peking Union Medical College Hematology Tianjin China
| | - R. Marcus
- Sarah Cannon Research Institute UK Oncology London UK
| | - C. Portell
- University of Virginia Health System Hematology/Oncology Charlottesville USA
| | - C. Thieblemont
- APHP, Hôpital Saint‐Louis, Hemato‐oncology Paris University Diderot Hematology/Oncology Paris France
| | - K. Zhou
- Henan Cancer Hospital Oncology Zhengzhou China
| | - A. M. Liberati
- Azienda Ospedaliera Santa Maria Di Terni Oncology Terni Italy
| | - E. Bachy
- Centre Hospitalier Lyon Sud Pierre Bénite Hematology Rhone Italy
| | - F. Cavallo
- Azienda Ospedaliera Città della Salute e della Scienza di Torino Hematology Torino Italy
| | - Rég. Costello
- Hôpital de la Conception – APHM Hematology Marseille France
| | - S. Iyengar
- Royal Marsden Hospital Haematology London UK
| | - R. Marasca
- AOU Policlinico di Modena Hematology Modena Italy
| | - H. Mociková
- Fakultní nemocnice Královské Vinohrady Hematology Praha 10 Czech Republic
| | - J. S. Kim
- Severance Hospital Hematology Seoul Korea
| | - D. Talaulikar
- The Canberra Hospital Haematology Canberra Australia
| | - M. Co
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - W. Zhou
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - J. Huang
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - S. Opat
- Monash Health Monash University Haematology Clayton Australia
| |
Collapse
|
9
|
Deux J, Meignan M, Chartier L, Judet A, Vercellino L, Casasnovas O, Baud V, Tilly H, Cottereau A, Thieblemont C. HIGH ADIPOSE TISSUE DENSITY IS A NEGATIVE PROGNOSTIC FACTOR IN DLBCL PATIENTS TREATED BY R‐CHOP, INDEPENDENT FROM TMTV AND PS –FROM THE REMARC STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.78_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J.‐F. Deux
- APHP, Hopital Henri Mondor, Radiologie Creteil France
| | - M. Meignan
- LYSA‐IM, Hopital Henri Mondor LYSA‐IM Paris France
| | | | - A. Judet
- APHP Saint‐Louis Hospital Hemato‐oncology Paris France
| | - L. Vercellino
- APHP Hopital Saint‐Louis Medecine Nucleaire Paris France
| | | | - V. Baud
- Université de Paris NF‐KappaB, différenciaation et Cancer Paris France
| | - H. Tilly
- Centre Henri Becquerel INSERM U1245 Rouen France
| | | | | |
Collapse
|
10
|
Thieblemont C, Deux J, Vercellino L, Chartier L, Casasnovas O, Judet A, Baud V, Tilly H, Cottereau A, Meignan M. DEFINING ULTRA‐HIGH‐RISK DLBCL PATIENTS PRIOR TO INITIAL TREATMENT BASED ON AN INTEGRATIVE HOST AND DISEASE PROGNOSTIC SCORE (FROM REMARC STUDY). Hematol Oncol 2021. [DOI: 10.1002/hon.17_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C Thieblemont
- APHP, Saint‐Louis Hospital Hemato‐oncology Paris France
| | - J.‐F Deux
- APHP, Hopital Henri Mondor Radiology Paris France
| | - L Vercellino
- APHP, Hopital Saint‐Louis Medecine Nucleaire Paris France
| | | | | | - A Judet
- APHP, Saint‐Louis Hospital Hemato‐oncology Paris France
| | - V Baud
- Université de Paris NF‐KappaB, différenciaation et Cancer Paris France
| | - Hervé Tilly
- Centre Henri Becquerel INSERM U1245 Rouen France
| | | | - M Meignan
- LYSA‐IM Hopital Henri Mondor LYSA‐IM Paris France
| |
Collapse
|
11
|
Cheminant M, Burroni B, Bris Y, Chartier L, Oberic L, Ribrag V, Delfau M, Thieblemont C, Gressin R, Canioni D, Peyre M, Laurent C, Steimle T, Kaltenbach S, Asnafi V, Macintyre E, Callanan M, Gouill S, Hermine O. HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.64_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Cheminant
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - B. Burroni
- Cochin University Hospital Pathology Paris France
| | - Y. Bris
- Nantes University Hospital Hematolobiology Nantes France
| | | | - L. Oberic
- Toulouse‐Oncopole University hospital Hematology Toulouse France
| | - V. Ribrag
- Gustave‐Roussy Hematology Villejuif France
| | - M.‐H. Delfau
- Mondor University Hospital Hematolobiology Créteil France
| | | | - R. Gressin
- Grenoble University Hospital Hematology Grenoble France
| | - D. Canioni
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - M. Peyre
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | | | - T. Steimle
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - S. Kaltenbach
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - V. Asnafi
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - E. Macintyre
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - M. Callanan
- Dijon University Hospital Hematobiology Dijon France
| | - S. Gouill
- Nantes University Hospital Hematology Nantes France
| | - O. Hermine
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| |
Collapse
|
12
|
Maerevoet M, Casasnovas O, Cartron G, Morschhauser F, Thieblemont C, Bouabdallah K, Feugier P, Szablewski V, Becker S, Tilly H. SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY ( EUDRACT NUMBER: 2015‐005612‐15). Hematol Oncol 2021. [DOI: 10.1002/hon.88_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Maerevoet
- Institut Jules Bordet ULB, Hematology Brussels Belgium
| | - O. Casasnovas
- CHU Dijon Bourgogne Hematology and INSERM 1231 Dijon France
| | - G. Cartron
- CHU Montpellier Hematology Montpellier France
| | | | | | | | | | - V. Szablewski
- CHU Montpellier Pathological Anatomy and Cytology Montpellier France
| | - S. Becker
- Centre Henri Becquerel Nuclear Medicine Rouen France
| | - H. Tilly
- Centre Henri Becquerel Hematology Rouen France
| |
Collapse
|
13
|
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Silva MG, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez‐Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Sabattini E, Salles G, Santambrogio E, Scarfó L, Stathis A, Stüssi G, Geyer JT, Tapia G, Thieblemont C, Tousseyn T, Tucci A, Visco C, Vitolo U, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, Leval L, Dirnhofer S, Pileri SA, Piris MÁ, Traverse‐Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.43_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
14
|
Bommier C, Ruggiu M, Monegier A, Zucca E, Thieblemont C, Lambert J. ENDPOINTS IN MARGINAL ZONE LYMPHOMAS: A SYSTEMATIC REVIEW REVEALS WIDE HETEROGENEITY ACROSS TRIALS AND CALLS FOR STANDARDIZATION. Hematol Oncol 2021. [DOI: 10.1002/hon.27_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C Bommier
- Hôpital Saint Louis Onco‐hematology department U1153 Inserm ‐ ECSTRRA Team Paris France
| | - M Ruggiu
- Hôpital Saint Louis Hematopoietic stem cell transplant Paris France
| | - A Monegier
- Hôpital Saint Louis, Statistics and Bioinformatics Paris France
| | - E Zucca
- Ospedale Regionale di Bellinzona e Valli, IELSG Bellinzona Switzerland
| | | | - J Lambert
- Hôpital Saint Louis, Statistics and Bioinformatics Inserm U1153 ECSTRRA Team Paris France
| |
Collapse
|
15
|
Herbaux C, Schiano de Colella JM, Thieblemont C, Guidez S, Ysebaert L, Tilly H, Gouill S, Houot R, Bachy E, Laurent C, Damaj G, Feugier P, Morineau N, Tarte K, Morschhauser F, Cartron G. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA. Hematol Oncol 2021. [DOI: 10.1002/hon.57_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C. Herbaux
- CHU Montpellier, Hématologie Clinique Montpellier France
| | | | | | | | | | - H. Tilly
- CHB Unicancer, Hematology Rouen France
| | | | | | | | | | | | | | - N. Morineau
- CHD Vendée, Hematology La Roche sur Yon France
| | | | | | - G. Cartron
- CHU Montpellier, Hématologie Clinique Montpellier France
| |
Collapse
|
16
|
Cartron G, Bachy E, Guidez S, Gyan E, Gressin R, Morineau N, Sibon D, Casasnovas O, Le Gouill S, Tilly H, Ysebaert L, Schiano de Colella JM, Feugier P, Virelizier EN, Haioun C, Damaj G, Tarte K, Laurent C, Houot R, Thieblemont C, Morschhauser F, Herbaux C. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA. Hematol Oncol 2021. [DOI: 10.1002/hon.22_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- G. Cartron
- CHU Montpellier Hématologie Cliniqu Montpellier France
| | | | | | | | | | - N. Morineau
- CHD Vendée Hematology La Roche sur Yon France
| | | | | | | | - H. Tilly
- CHB Unicancer Hematology Rouen France
| | | | | | | | | | | | | | | | | | | | | | | | - C. Herbaux
- CHU Montpellier Hématologie Cliniqu Montpellier France
| |
Collapse
|
17
|
Thieblemont C, Clausen MR, Balari AS, Zinzani PL, Fox CP, Kim SY, Vindelov SD, Lugtenburg P. PHASE 3 TRIAL (GCT3013‐05) OF EPCORITAMAB VERSUS STANDARD OF CARE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematol Oncol 2021. [DOI: 10.1002/hon.162_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Thieblemont
- Assistance Publique & Hôpitaux de Paris (APHP) Hopital Saint‐Louis Université de Paris Hemato‐Oncology Department Paris France
| | - M. R. Clausen
- Vejle Hospital Department of Hematology Vejle Denmark
| | - A. S. Balari
- Institut Català d'Oncologia‐Hospital Duran i Reynals IDIBELL Universitat de Barcelona Hospitalet del Llobregat Department of Hematology Barcelona Spain
| | - P. L. Zinzani
- Lymphoma and Chronic Lymphoproliferative Syndromes Unit Institute of Hematology "L. e A. Seràgnoli," University of Bologna Department of Experimental Diagnostic and Specialty Medicine Bologna Italy
| | - C. P. Fox
- Nottingham University Hospitals NHS Trust UK Department of Clinical Haematology Nottingham UK
| | - S. Y. Kim
- AbbVie, Clinical Development North Chicago Illinois USA
| | | | - P. Lugtenburg
- On behalf of the HOVON/Lymphoma Working Group Erasmus MC Cancer Institute Department of Hematology Rotterdam Netherlands
| |
Collapse
|
18
|
Camus V, Belot A, Oberic L, Sibon D, Ghesquières H, Thieblemont C, Fruchart C, Casasnovas O, Michot J, Molina TJ, Bosly A, Joubert C, Haioun C, Delarue R, Tilly H. LONG‐TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLINE R‐CHOP: UPDATE OF THE LNH03‐6B TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.96_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- V. Camus
- Centre Henri Becquerel Department of Hematology Rouen France
| | | | - L. Oberic
- IUCT Oncopole Hematology Toulouse France
| | - D. Sibon
- CHU Necker hematology Paris France
| | | | | | | | | | | | | | - A. Bosly
- UCL Mont‐Godinne Hematology Namur Belgium
| | | | - C. Haioun
- CHU Mondor Hematology Créteil France
| | | | - H. Tilly
- Centre Henri Becquerel Department of Hematology Rouen France
| |
Collapse
|
19
|
Bohers E, Delfau‐Larue M, Vercellino L, Cottereau A, Viennot M, Viailly P, Salles G, Tilly H, Damaj G, Haioun C, Ribrag V, Morschhauser F, Casasnovas R, Nicolas‐Virelizier E, Feugier P, Bouabdallah R, Cartron G, Renaud L, Chartier L, Portugues C, Meignan M, Jardin F, Thieblemont C. CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.3_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- E Bohers
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors INSERM U1245, Normandy University Rouen France
| | - M Delfau‐Larue
- Hematobiology and Immunobiology Department INSERM U955 Eq9, APHP University Hospital Henri Mondor Créteil France
| | - L Vercellino
- Department of Nuclear C, APHP Saint‐Louis Hospital Paris France
| | - A Cottereau
- Department of Nuclear Medicine APHP, Cochin Paris France
| | - M Viennot
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors INSERM U1245, Normandy University Rouen France
| | - P Viailly
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors INSERM U1245, Normandy University Rouen France
| | - G Salles
- Memorial Sloan Kettering Cancer Center Lymphoma Department New York New York USA
| | - H Tilly
- Department of Hematology Henri Becquerel Center Rouen France
| | - G Damaj
- Department of Hematology Caen University Hospital Caen France
| | - C Haioun
- Department of Hematology Henri Mondor University Hospital Créteil France
| | - V Ribrag
- Department of Hematology Gustave Roussy Institute Villejuif France
| | - F Morschhauser
- Department of Hematology Lille University Hospital Lille France
| | - R Casasnovas
- Department of Hematology Dijon University Hospital Dijon France
| | | | - P Feugier
- Department of Hematology Nancy university Hospital Vandoeuvre‐les‐Nancy France
| | - R Bouabdallah
- Department of Hematology Paoli Calmette Institute Marseille France
| | - G Cartron
- Department of Hematology Montpellier University Hospital Montpellier France
| | - L Renaud
- Department of Hematology Lille University Hospital Lille France
| | - L Chartier
- LYSARC, Lyon Hospital Pierre‐Benite France
| | | | - M Meignan
- Department of Nuclear Medicine APHP, University Hospital Henri Mondor Creteil France
| | - F Jardin
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors INSERM U1245, Normandy University Rouen France
| | - C Thieblemont
- Department of Hematology APHP, Saint‐Louis Hospital Paris France
| |
Collapse
|
20
|
Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†. Ann Oncol 2021; 32:404-411. [DOI: 10.1016/j.annonc.2020.11.019] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 11/05/2020] [Accepted: 11/17/2020] [Indexed: 10/22/2022] Open
|
21
|
Moulin C, Guillemin F, Remen T, Bouclet F, Augé H, Quinquenel A, Dartigeas C, Morizot R, Lomazzi S, Busby H, Hergalant S, Tausch E, Tomowiak C, Roos-Weil D, Thieblemont C, Cymbalista F, Laribi K, Béné MC, Stilgenbauer S, Guièze R, Feugier P, Broséus J. Facteurs pronostiques clinico-biologiques et génomiques de la survie dans le syndrome de Richter. Rev Epidemiol Sante Publique 2021. [DOI: 10.1016/j.respe.2020.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
22
|
Severyns T, Kirchgesner J, Lambert J, Thieblemont C, Amiot A, Abitbol V, Treton X, Cazals-Hatem D, Malamut G, Coppo P, Galicier L, Walter-Petrich A, Deau-Fischer B, Besson C, Aparicio T, Beaugerie L, Allez M, Gornet JM. Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study. J Crohns Colitis 2020; 14:1222-1230. [PMID: 32161943 DOI: 10.1093/ecco-jcc/jjaa048] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
BACKGROUND AND AIMS The prognosis of lymphoma that occurs in patients with inflammatory bowel disease [IBD] is poorly known. METHODS A multicentre retrospective cohort analysis was done in seven French tertiary centres from 1999 to 2019. Only lymphoma occurring in patients with previous established diagnosis of IBD were analysed. The primary outcome was progression-free survival at 3 years. RESULTS A total of 52 patients [male 65%, Crohn's disease 79%, median age 48.3 years, median duration of IBD 10.1 years] were included, of whom 37 had been previously exposed to immunosuppressants and/or biologics for at least 3 months and 20 had primary intestinal lymphomas. The lymphoma histological types were: diffuse large B cell lymphomas [N = 17], Hodgkin lymphomas [N = 17], indolent B cell lymphomas [N = 12], and others including T cell lymphomas, mantle cell lymphomas, and unclassifiable B cell lymphoma [N = 6]. The median follow-up after lymphoma was 5.1 years (interquartile range [IQR] 4-7.8). Progression-free survival at 3 years was 85% in the overall population (95% confidence interval [CI] 75%-96%) with no significant difference between the exposed and unexposed group, 79% for patients exposed to immunosuppressants and/or biologics [95% CI 67%-94%], and 83% for patients diagnosed with primary intestinal lymphoma [95% CI 67%-100%]. No relapse of IBD has been observed during chemotherapy. The IBD relapse rate at the end of the last chemotherapy cycle was 23% at 3 years [95% CI 11%-39%] in the overall population. CONCLUSIONS In this large cohort, the prognosis for lymphomas occurring in IBD appears to be good and similar to what is expected, irrespective of the exposure to biologics and/or immunosuppressants.
Collapse
Affiliation(s)
- T Severyns
- Service de Gastroentérologie, Hôpital Saint Louis, Université de Paris, Paris, France
| | - J Kirchgesner
- Service de Gastroentérologie, Hôpital Saint-Antoine, Sorbonne Université, Paris, France
| | - J Lambert
- Service de Biostatistiques et Information Médicale, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - C Thieblemont
- Service d'Hémato-oncologie, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - A Amiot
- Service de Gastroentérologie, Hôpital Henri Mondor, UPEC, Créteil, France
| | - V Abitbol
- Service de Gastroentérologie, Hôpital Cochin, Université de Paris, Paris, France
| | - X Treton
- Service de Gastroentérologie, Hôpital Beaujon, Université de Paris, Clichy La Garenne, France
| | - D Cazals-Hatem
- Département de Pathologie, Hôpital Beaujon, Université de Paris, Clichy La Garenne. France
| | - G Malamut
- Service de Gastroentérologie, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France
| | - P Coppo
- Service d'Hématologie, Hôpital Saint-Antoine, Sorbonne Université, Paris, France
| | - L Galicier
- Service d'Immunohématologie, Hôpital Saint Louis, Université de Paris, Paris, France
| | - A Walter-Petrich
- Service de Biostatistiques et Information Médicale, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - B Deau-Fischer
- Service d'Hématologie, Hôpital Cochin, Université de Paris, Paris, France
| | - C Besson
- Service d'Hématologie-Oncologie, Centre Hospitalier de Versailles, Université Versailles Saint Quentin en Yvelines, Université de Paris-Saclay, Le Chesnay, France
| | - T Aparicio
- Service de Gastroentérologie, Hôpital Saint Louis, Université de Paris, Paris, France
| | - L Beaugerie
- Service de Gastroentérologie, Hôpital Saint-Antoine, Sorbonne Université, Paris, France
| | - M Allez
- Service de Gastroentérologie, Hôpital Saint Louis, Université de Paris, Paris, France
| | - J M Gornet
- Service de Gastroentérologie, Hôpital Saint Louis, Université de Paris, Paris, France
| |
Collapse
|
23
|
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 31:17-29. [PMID: 31912792 DOI: 10.1016/j.annonc.2019.10.010] [Citation(s) in RCA: 150] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Revised: 10/07/2019] [Accepted: 10/09/2019] [Indexed: 02/08/2023] Open
Affiliation(s)
- E Zucca
- Division of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - C Buske
- Comprehensive Cancer Centre, University Hospital of Ulm, Ulm, Germany
| | - P W Johnson
- Cancer Research UK Centre, Southampton General Hospital, Southampton, UK
| | - M Ponzoni
- Vita-Salute San Raffaele University and Pathology Unit, San Raffaele Scientific Institute, Milan, Italy
| | - M Raderer
- Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria
| | - U Ricardi
- Department of Oncology, University of Turin, Turin, Italy
| | - A Salar
- Department of Hematology, Hospital del Mar, Barcelona, Barcelona, Spain
| | - K Stamatopoulos
- Institute of Applied Biosciences, CERTH, the Centre for Research and Technology Hellas, Thessaloniki, Greece
| | - C Thieblemont
- Department of Hematology, APHP-Saint-Louis Hospital, University Paris-Diderot, Paris, France
| | - A Wotherspoon
- Department of Histopathology, The Royal Marsden Hospital, London, UK
| | - M Ladetto
- Division of Hematology, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | | |
Collapse
|
24
|
Milcent B, Josseaume N, Petitprez F, Riller Q, Amorim S, Loiseau P, Toubert A, Brice P, Thieblemont C, Teillaud JL, Sibéril S. Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen. Sci Rep 2019; 9:13471. [PMID: 31530876 PMCID: PMC6748924 DOI: 10.1038/s41598-019-50029-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Accepted: 09/04/2019] [Indexed: 02/08/2023] Open
Abstract
Preclinical models and clinical studies have shown that anti-CD20-based treatment has multifaceted consequences on T-cell immunity. We have performed a prospective study of peripheral T-cell compartment in FL patients, all exhibiting high tumor burden and receiving rituximab-chemotherapy-based regimen (R-CHOP). Before treatment, FL patients harbor low amounts of peripheral naive T cells, but high levels of CD4+ TEM, CD4+ Treg and CD8+ TEMRA subsets and significant amounts of CD38+ HLA-DR+ activated T cells. A portion of these activated/differentiated T cells also expressed PD-1 and/or TIGIT immune checkpoints. Hierarchical clustering of phenotyping data revealed that 5/8 patients with only a partial response to R-CHOP induction therapy or with disease progression segregate into a group exhibiting a highly activated/differentiated T cell profile and a markedly low proportion of naive T cells before treatment. Rituximab-based therapy induced a shift of CD4+ and CD8+ T cells toward a central memory phenotype and of CD8+ T cells to a naive phenotype. In parallel, a decrease in the number of peripheral T cells expressing both PD-1 and TIGIT was detected. These observations suggest that the standard rituximab-based therapy partially reverts the profound alterations observed in T-cell subsets in FL patients, and that blood T-cell phenotyping could provide a better understanding of the mechanisms of rituximab-based treatment.
Collapse
Affiliation(s)
- B Milcent
- Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.,Sorbonne Université, UMR-S 1138, Paris, 75006, France.,Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France
| | - N Josseaume
- Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.,Sorbonne Université, UMR-S 1138, Paris, 75006, France.,Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France
| | - F Petitprez
- Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.,Sorbonne Université, UMR-S 1138, Paris, 75006, France.,Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France.,Ligue Nationale Contre le Cancer, Programme Cartes d'Identité des Tumeurs, Paris, 75014, France
| | - Q Riller
- Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.,Sorbonne Université, UMR-S 1138, Paris, 75006, France.,Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France
| | - S Amorim
- APHP, Saint-Louis Hospital, Hemato-oncology - Diderot University, Sorbonne Paris Cité, Paris, France
| | - P Loiseau
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.,Inserm UMR-S 1160, Paris, France.,Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, 7, France
| | - A Toubert
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.,Inserm UMR-S 1160, Paris, France.,Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, 7, France
| | - P Brice
- APHP, Saint-Louis Hospital, Hemato-oncology - Diderot University, Sorbonne Paris Cité, Paris, France
| | - C Thieblemont
- APHP, Saint-Louis Hospital, Hemato-oncology - Diderot University, Sorbonne Paris Cité, Paris, France.,EA7324 Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - J-L Teillaud
- Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.,Sorbonne Université, UMR-S 1138, Paris, 75006, France.,Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France.,Laboratory "Immune Microenvironment and Biotherapy", Sorbonne University UMRS1135, INSERM U.1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Paris, France
| | - S Sibéril
- Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France. .,Sorbonne Université, UMR-S 1138, Paris, 75006, France. .,Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France.
| |
Collapse
|
25
|
Belin C, Simard C, Dos Santos A, Ayrignac X, Berger C, Cartron G, Le Gouill S, Sesques P, Thieblemont C, Carpentier AF. JS1.4 Neurological follow-up of neurotoxicity after CAR T cell therapy in lymphoma patients: A French neurological multi-center survey. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Chimeric antigen receptor-modified T (CAR T) cell therapy is a highly promising treatment for haematological malignancies but is frequently associated with cytokine-release syndrome (CRS) and neurotoxicity. The physiopathological mechanisms of neurological complications and their links with CRS remain largely unknown. The aims of this study are: a) to follow-up longitudinally patients treated with CAR-T cell therapy; b) to exhaustively identify neurological signs and symptoms and; c) to describe their occurrence over time.
MATERIAL AND METHODS
Since September 2018, all patients treated with CD19-targeted CAR T cell therapy for relapsing lymphoma were systematically followed-up and monitored for signs of neurotoxicity by a neurologist. Five different centres (Paris-Saint-Louis, Nantes, Lyon, Montpellier, and Rennes) participated in this study.
RESULTS
As of April 1st 2019, 57 patients, mean age 49 years (range from 22 to 72 years, median age 50 years), 22 females / 35 males, all treated for lymphoma, were included in this study Neurotoxicity, defined as the presence of at least one neurological sign or symptoms appearing after treatment infusion, was present in 33 % of patients. The median time to onset was 7.5 days after infusion with a median duration of symptoms of 5 days. Neurological symptoms were: Encephalopathy (52%), cerebellar syndrome (26%), aphasia (15%), agraphia (15%), executive syndrome (10%), myoclonus (10%), dysarthria (10%), meningismus (5%), transverse myelitis (5%), seizure (5%), neuralgia (5%), and dysesthesia (5%). The severity grade of neurotoxicity was grade 4: 2 patients, Grade 3: 7 patients, grade 2: 5 patients and grade 1: 5 patients (CTCAE grading). CRS was observed in 75% of patients. All patients who developed neurological disorders also had CRS (grade 1: 68%, grade 2: 10%, grade 3: 15%, grade 4: 5%) that preceded neurotoxicity. As the study is still ongoing, updated results will be presented at the EANO meeting.
CONCLUSION
Neurotoxicity associated with CAR-T therapies occurs in one third of patients. This high frequency underlines the need: 1 - to neurologically assess all patients before and repeatedly after therapy infusions; 2 - to provide guidelines for neurological assessment and relevant investigations to improve early recognition of neurotoxicity and its management
Collapse
Affiliation(s)
- C Belin
- Hopital Saint-Louis AP-HP, Paris, France
| | - C Simard
- Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
| | | | | | - C Berger
- Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
| | - G Cartron
- CHU Montpellier, Montpellier, France
| | | | - P Sesques
- Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
| | | | | |
Collapse
|
26
|
Rusconi C, Tucker D, Bernard S, Muzi C, Crucitti L, Stefani P, Cox M, Gini G, Re A, Sciarra R, Liberati A, Morello L, Arcari A, Mannina D, Vitagliano O, Sartori R, Chiappella A, Balzarotti M, Vitolo U, Thieblemont C, Rule S, Visco C. IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.54_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C. Rusconi
- Division of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milan Italy
| | - D. Tucker
- Department of Haematology; Royal Cornwall NHSTrust; Truro Cornwall United Kingdom
| | - S. Bernard
- Service d'Onco-Hématologie; Hôpital Saint-Louis, AP-HP; Paris France
| | - C. Muzi
- Division of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milan Italy
| | - L. Crucitti
- Division of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milan Italy
| | - P. Stefani
- U.O.C. di Ematologia; Dipartimento di Medicina Specialistica, Unità Locale Socio-Sanitaria della Marca Trevigiana; Treviso Italy
| | - M. Cox
- Haematology Unit, Department of Clinical and Experimental Medicine; Sapienza University, AO Sant'Andrea; Rome Italy
| | - G. Gini
- Division of Hematology; Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona; Ancona Italy
| | - A. Re
- U.O. Ematologia; Spedali Civili di Brescia; Brescia Italy
| | - R. Sciarra
- Division of Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - A. Liberati
- Università di Perugia; AO Santa Maria di Terni; Terni Italy
| | - L. Morello
- Department of Medica Oncology and Hematology; Humanitas Clinical and Research Center - IRCCS; Rozzano Milan Italy
| | - A. Arcari
- Hematology Unit; Ospedale Guglielmo da Saliceto; Piacenza Italy
| | - D. Mannina
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - O. Vitagliano
- Division of Hematology; Cardarelli Hospital; Naples Italy
| | - R. Sartori
- Hematology Department; Castelfranco Veneto Hospital, ULSS 2 Marca Trevigiana, Castelfranco Veneto; Treviso Italy
| | - A. Chiappella
- Hematology; AO Città della Salute e della Scienza di Torino; Turin Italy
| | - M. Balzarotti
- Department of Medica Oncology and Hematology; Humanitas Clinical and Research Center - IRCCS; Rozzano Milan Italy
| | - U. Vitolo
- Hematology; AO Città della Salute e della Scienza di Torino; Turin Italy
| | - C. Thieblemont
- Service d'Onco-Hématologie; Hôpital Saint-Louis, AP-HP; Paris France
| | - S. Rule
- Plymouth University; Peninsula Schools of Medicine ad Dentistry; Plymouth United Kingdom
| | - C. Visco
- Department of Medicine; Section of Hematology, University of Verona; Verona Italy
| |
Collapse
|
27
|
Topp M, Van Meerten T, Wermke M, Lugtenburg P, Minnema M, Song K, Thieblemont C, Jiang Y, Plaks V, Kerber A, Kersten M. PRELIMINARY RESULTS OF EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.114_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M.S. Topp
- Medizinische Klinik und Poliklinik II; Universitätsklinikum Würzburg; Würzburg Germany
| | - T. Van Meerten
- Department of Hematology; University Medical Center Groningen on behalf of HOVON/LLPC (Lunenburg Lymphoma Phase I/II Consortium); Groningen Netherlands
| | - M. Wermke
- Medical Department I; University Hospital Carl Gustav Carus; Dresden Germany
| | - P.J. Lugtenburg
- Lunenburg Lymphoma Phase I/II Consortium - HOVON /LLPC; Erasmus MC; Rotterdam Netherlands
| | - M.C. Minnema
- Department of Medical Oncology; University Medical Center Utrecht on behalf of HOVON/LLPC (Lunenburg Lymphoma Phase I/II Consortium); Utrecht Netherlands
| | - K.W. Song
- Division of Hematology
- Department of Medicine; The University of British Columbia; Vancouver Canada
| | - C. Thieblemont
- Service Onco-Hematologie; Hôpital Saint Louis; Paris France
| | - Y. Jiang
- Biostatistics; Kite, a Gilead Company; Santa Monica United States
| | - V. Plaks
- Cell Biology; Kite, a Gilead Company; Santa Monica United States
| | - A. Kerber
- Clinical Development; Kite, a Gilead Company; Santa Monica United States
| | - M.J. Kersten
- Internal Medicine; Academic Medical Center University of Amsterdam on behalf of HOVON/LLPC (Lunenburg Lymphoma Phase I/II Consortium); Amsterdam Netherlands
| |
Collapse
|
28
|
Zoellner A, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Kluin-Nelemans H, Hiddemann W, Dreyling M, Hoster E. AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION-FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.13_2629] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Zoellner
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Unterhalt
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - S. Stilgenbauer
- Department of Internal Medicine I; University Hospital of Homburg; Homburg Germany
| | - K. Hübel
- Department of Medicine I; University Hospital of Cologne; Cologne Germany
| | - C. Thieblemont
- Hemato-Oncology Department; Diderot University; Hôpital Saint-Louis Paris France
| | - B. Metzner
- Department of Hematology/Oncology; University Hospital Oldenburg; Oldenburg Germany
| | | | - W. Hiddemann
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Dreyling
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - E. Hoster
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| |
Collapse
|
29
|
Thieblemont C, Le Gouill S, Di Blasi R, Cartron G, Morschhauser F, Bachy E, Paillassa J, Bernard S, Tessoulin B, Gastine T, Fegueux N, Kanouni T, Manier S, Sesques P, Houot R, Haouin C, Tilly H, Salles G. REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM. Hematol Oncol 2019. [DOI: 10.1002/hon.110_2630] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | - R. Di Blasi
- Hematology; APHP; Saint-Louis Hospital Paris France
| | - G. Cartron
- Hematology; CHU Montpellier; Montpellier France
| | | | - E. Bachy
- Hematology; CHU Lyon; Pierre-Benite France
| | - J. Paillassa
- Hematology; APHP; Saint-Louis Hospital Paris France
| | - S. Bernard
- Hematology; APHP; Saint-Louis Hospital Paris France
| | | | | | - N. Fegueux
- Hematology; CHU Montpellier; Montpellier France
| | - T. Kanouni
- Hematology; CHU Montpellier; Montpellier France
| | - S. Manier
- Hematology; CHU Montpellier; Montpellier France
| | - P. Sesques
- Hematology; CHU Lyon; Pierre-Benite France
| | - R. Houot
- Hematology; CHU Rennes; Rennes France
| | - C. Haouin
- Hematology; APHP; Henri Mondor Hospital, Créteil France
| | - H. Tilly
- Hematology; Centre H. Becquerel; Rouen France
| | - G. Salles
- Hematology; CHU Lyon; Pierre-Benite France
| |
Collapse
|
30
|
Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat J, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho J, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos T, Warzocha K, Oluyadi A, McCarthy D, Ma X, Corona K, Shah J, Van Den Neste E, Canales M. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2019. [DOI: 10.1002/hon.31_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - F. Cavallo
- Molecular Biotechnology and Health Sciences; Aziena Ospedaliero - Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - G. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital; Cambridge United Kingdom
| | - A. Goy
- Oncology; Hackensack University Medical Center; Hackensack United States
| | - J. Vermaat
- Hematology; Leiden University Medical Center; Leiden Netherlands
| | | | - O. Lavee
- Hematology; St. Vincent's Hospital Sydney; Darlinghurst Australia
| | - M. Maerevoet
- Hematology; Service Hématologie, Institut Bordet; Bruxelles Belgium
| | - J. Zijlstra
- Hematology; Amsterdam UMC; Amsterdam Netherlands
| | - S. Bakshi
- Medical Oncology; Dr. B. R. A. Institute Rotary Cancer Hospital; New Delhi India
| | - R. Bouabdallah
- Oncology/Hematology; Institut Paoli-Calmettes; Marseille France
| | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - R. Gurion
- Hematology; Rabin MC; Petah Tiqwa Israel
| | - B. Hill
- Hematology and Medical Oncology; Cleveland Clinic Main Campus; Cleveland United States
| | - U. Jaeger
- Medicine I; Medical University of Vienna; Vienna Austria
| | - J. Sancho
- Clinical Hematology; Hospital Germans Trias i Pujol; Barcelona Spain
| | - M. Schuster
- Medicine; Stony Brook University; Stony Brook United States
| | | | - F. De la Cruz
- Hematology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - M. Egyed
- Hematology; Teaching Hospital Mór Kaposi; Kaposvár Hungary
| | - S. Mishra
- Medical Oncology; Institute of Medical Sciences & SUM Hospital; Bhubaneswar India
| | | | | | - K. Warzocha
- Hematology; Instytut Hematologii i Transfuzjologii; Warszawa Poland
| | - A. Oluyadi
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - D. McCarthy
- Clinical Operations; Karyopharm Therapeutics Inc.; Newton United States
| | - X. Ma
- Biostatistics; Karyopharm Therapeutics Inc.; Newton United States
| | - K. Corona
- Medical Affairs; Karyopharm Therapeutics Inc.; Newton United States
| | - J. Shah
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - E. Van Den Neste
- Hematology; Cliniques Universitaires Saint-Luc; Brussels Belgium
| | - M. Canales
- Medicine; Hospital Universitario La Paz; Madrid Spain
| |
Collapse
|
31
|
Cottereau A, Vercellino L, Casasnovas O, Tilly H, Feugier P, Fruchart C, Roulin L, Oberic L, Pica G, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban C, Lopez A, Macro M, Sahnes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Copie-Bergman C, Briere J, Salles G, Gaulard P, Meignan M, Thieblemont C. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.19_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - L. Vercellino
- Medecine Nucleaire; APHP, Saint-Louis Hospital; Paris France
| | | | - H. Tilly
- Hematology; Centre H. Becquerel; Rouen France
| | - P. Feugier
- Hematology; CHU Brabois - Nancy; Nancy France
| | | | - L. Roulin
- Hematology; APHP, Henri Mondor Hospital; Créteil France
| | - L. Oberic
- Hematology; CHU Toulouse; Toulouse France
| | - G. Pica
- Hematology; CHU Annecy; Annecy France
| | | | | | - M. Simon
- Hematology; CH Valenciennes; Valenciennes France
| | | | | | - O. Fitoussi
- Hematology; Hopital Bordeaux Nord; Bordeaux France
| | - C. Sebban
- Hematology; Centre L. Berard; Lyon France
| | - A. Lopez
- Hematology; IOB; Barcelona Spain
| | - M. Macro
- Hematology; CHU Caen; Caen France
| | - L. Sahnes
- Hematology; CH Perpignan; Perpignan France
| | | | - J. Trotman
- Hematology; Concord Hospital; Sydney Australia
| | | | - B. Choufi
- Hematology; CH Boulogne; Boulogne France
| | | | - P. Godmer
- Hematology; CH Vannes; Vannes France
| | | | - J. Briere
- Pathology; APHP, Saint-Louis Hospital; Paris France
| | - G. Salles
- Hematology; CHU Lyon; Pierre-Benite France
| | - P. Gaulard
- Pathology; APHP, Henri Mondor Hospital; Créteil France
| | - M. Meignan
- Medecine Nucleaire; APHP, Henri Mondor Hospital; Créteil France
| | | |
Collapse
|
32
|
Conconi A, Thieblemont C, Cascione L, Torri V, Kiesewetter B, Margiotta-Casaluci G, Gaidano G, Raderer M, Cavalli F, Lopez Guillermo A, Johnson P, Zucca E. EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT. Hematol Oncol 2019. [DOI: 10.1002/hon.136_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Conconi
- Division of Hematology; Ospedale degli Infermi; Ponderano Italy
| | - C. Thieblemont
- Hemato-Oncology Department; Saint Louis Hospital; Paris France
| | - L. Cascione
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - V. Torri
- Clinical Research Methodology Laboratory; IRCCS-Mario Negri Institute; Milan Italy
| | - B. Kiesewetter
- Division of Oncology; Department of Internal Medicine I, Medical University of Vienna; Vienna Austria
| | - G. Margiotta-Casaluci
- Division of Hematology, Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - G. Gaidano
- Division of Hematology, Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - M. Raderer
- Division of Oncology; Department of Internal Medicine I, Medical University of Vienna; Vienna Austria
| | - F. Cavalli
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | | | - P.W. Johnson
- Cancer Research UK Center; Southampton General Hospital; Southampton United Kingdom
| | - E. Zucca
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
33
|
Bossard C, Laghmari O, Le Bris Y, Bonnet A, Moreau A, El Alami Thomas W, Pavageau A, Guerzider P, Maisonneuve H, Ruminy P, Bene M, Casasnovas O, Canioni D, Thieblemont C, Petrella T, Jardin F, Salles G, Tilly H, Gaulard P, Haioun C, Brière J, Le Gouill S, Copie Bergman C, Molina T. REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE. Hematol Oncol 2019. [DOI: 10.1002/hon.11_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C. Bossard
- Department of Pathology; University Hospital of Nantes; Nantes France
| | - O. Laghmari
- Department of Pathology; University Hospital of Nantes; Nantes France
| | - Y. Le Bris
- Department of Hematology Biology; University Hospital of Nantes; Nantes France
| | - A. Bonnet
- Department of Hematology; University Hospital of Nantes; Nantes France
| | - A. Moreau
- Department of Pathology; University Hospital of Nantes; Nantes France
| | | | - A. Pavageau
- Department of Pathology; Centre Hospitalier de la Roche sur Yon; La Roche sur Yon France
| | - P. Guerzider
- Department of Pathology; Centre Hospitalier de Saint Nazaire; Saint Nazaire France
| | - H. Maisonneuve
- Department of Hematology; Centre Hospitalier de la Roche sur Yon; La Roche sur Yon France
| | - P. Ruminy
- INSERM U918; Centre Henri Becquerel; Rouen France
| | - M. Bene
- Department of Hematology Biology; University Hospital of Nantes; Nantes France
| | - O. Casasnovas
- Department of Hematology; University Hospital; Dijon France
| | - D. Canioni
- Department of Pathology; Hopital Necker Enfants Malades; Paris France
| | - C. Thieblemont
- Hemato-oncology Department; Hopital Saint Louis; Paris France
| | - T. Petrella
- Department of Medical Oncology; Odette Cancer Center; Toronto Canada
| | - F. Jardin
- Department of Hematology; Centre Henri Becquerel; Rouen France
| | - G. Salles
- Department of Hematology; Hospice Civils de Lyon; Lyon France
| | - H. Tilly
- Department of Hematology; Centre Henri Becquerel; Rouen France
| | - P. Gaulard
- Department of Pathology; Groupe Hospitalier Henri Mondor; Creteil France
| | - C. Haioun
- Department of Hematology; Groupe Hospitalier Henri Mondor; Creteil France
| | - J. Brière
- Hemato-oncology Department; Hopital Saint Louis; Paris France
| | - S. Le Gouill
- Department of Hematology; University Hospital of Nantes; Nantes France
| | - C. Copie Bergman
- Department of Pathology; Groupe Hospitalier Henri Mondor; Creteil France
| | - T.J. Molina
- Department of Pathology; Hopital Necker Enfants Malades; Paris France
| |
Collapse
|
34
|
Thieblemont C, Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, Moreira C, Czuczman M, Kalambakas S, Fustier P, Wu C, Gribben J. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R 2
) VS RITUXIMAB/PLACEBO (AUGMENT). Hematol Oncol 2019. [DOI: 10.1002/hon.41_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Thieblemont
- Hemato-Oncology; APHP, Hopital Saint-Louis; Paris France
| | - J. Leonard
- Meyer Cancer Center; Weill Cornell Medicine and New York Presbyterian Hospital; New York United States
| | - M. Trneny
- General Hospital; Charles University; Prague Czech Republic
| | - K. Izutsu
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - N. Fowler
- Department of Lymphoma and Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - X. Hong
- Hematology; Fudan University Shanghai Cancer Center; Shanghai China
| | - H. Zhang
- Hematology; Tianjin Medical University Cancer Institute and Hospital; Tianjin China
| | | | - A. Scheliga
- Hematology; INCA Instituto Nacional De Câncer; Rio de Janeiro Brazil
| | - G. Nowakowski
- Division of Hematology; Department of Internal Medicine, Mayo Clinic; Rochester United States
| | - A. Pinto
- Hematology; Istituto Nazionale Tumori, Fondazione ‘G. Pascale’, IRCCS; Naples Italy
| | - F. Re
- Hematology; Azienda Ospedaliero-Universitaria di Parma; Parma Italy
| | - L. Fogliatto
- Hematology; Hospital de Clinicas de Porto Alegre; Porto Alegre Brazil
| | - P. Scheinberg
- Hematology; Hospital A Beneficência Portuguesa de São Paulo; São Paulo Brazil
| | - I. Flinn
- Hematology; Sarah Cannon Research Institute/Tennessee Oncology; Nashville United States
| | - C. Moreira
- Hematology; Instituto Português de Oncologia Do Porto Francisco Gentil Epe; Porto Portugal
| | - M. Czuczman
- Global Clinical R&D Hematology/Oncology; Celgene Corporation; Summit United States
| | - S. Kalambakas
- Global Medical Affairs; Celgene Corporation; Summit United States
| | - P. Fustier
- Global Medical Affairs; Celgene International Sarl; Boudry Switzerland
| | - C. Wu
- BioStatistics; Celgene Corporation; Summit United States
| | - J. Gribben
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| |
Collapse
|
35
|
Dickinson M, Popplewell L, Kolstad A, Ho P, Teshima T, Dreyling M, Schuster S, Thieblemont C, Ghosh M, Riedell P, Yateman N, Lehnhoff K, Lawniczek T, Pacaud L, Fowler N. ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.6_2632] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Dickinson
- Integrated Haematology Service; Peter MacCallum Cancer Centre; Melbourne Australia
| | - L. Popplewell
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope National Medical Center; Duarte United States
| | - A. Kolstad
- Department of Oncology; Oslo University Hospital; Oslo Norway
| | - P.J. Ho
- Institute of Haematology; Royal Prince Alfred Hospital; Camperdown Australia
| | - T. Teshima
- Department of Hematology; Hokkaido University Hospital; Sapporo Japan
| | - M. Dreyling
- Department of Medicine; University Hospital Grosshadern; München Germany
| | - S. Schuster
- Division of Hematology Oncology; University of Pennsylvania; Philadelphia United States
| | - C. Thieblemont
- Hemato-Oncology Department; Hospital Saint-Louis; Paris France
| | - M. Ghosh
- Michigan Medicine Bone Marrow Transplant and Leukemia; University of Michigan; Ann Arbor United States
| | - P. Riedell
- Biomedical Sciences; University of Chicago; Chicago United States
| | - N. Yateman
- External; Novartis Pharma AG; Basel Switzerland
| | - K. Lehnhoff
- Global Development Operations; Novartis Pharma AG; Basel Switzerland
| | - T. Lawniczek
- CAR-T Cell Therapy; Novartis Pharma AG; Basel Switzerland
| | - L. Pacaud
- Novartis Oncology; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - N. Fowler
- Lymphoma and Meyloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
36
|
Le Gouill S, Beldi-Ferchiou A, Cacheux V, Salles G, Canioni D, Bodet-Milin C, Alcantara M, Delwail V, Gastinne T, Thieblemont C, Maisonneuve H, Lamy de la Chapelle T, Oberic L, Bouabdallah K, Ribrag V, Delfau-Larue M, Macintyre E, Hermine O. OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA-101 TRIAL, A LYSA GROUP STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.14_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - V. Cacheux
- Hematologie; CHU Clermont-Ferrand; Clermont-Ferrand France
| | | | | | | | | | - V. Delwail
- Hematology Biology; CHU Poitiers; Poitiers France
| | | | | | - H. Maisonneuve
- Hematology-Oncology; CH Roche-Sur-Yon; Roche-Sur-Yon France
| | | | - l. Oberic
- Hematology; Oncopole de Toulouse; Toulouse France
| | | | - V. Ribrag
- Hematology; Institut Gustave Roussy; Villejuif France
| | | | - E. Macintyre
- Hématologie Biologique; Hôpital Necker; Paris France
| | - O. Hermine
- Hematologie; Hôpital Necker; Paris France
| |
Collapse
|
37
|
Ferrero S, Ladetto M, Beldjord K, Drandi D, Stelitano C, Bernard S, Castagnari B, Bouabdallah K, Cesaretti M, Alvarez I, Gressin R, Ponzoni M, Tripodo C, Traverse-Glehen A, Baseggio L, Liberati A, Merli M, Tessoulin B, Patti C, Cabras M, Feugier P, Pozzi S, Zucca E, Iannitto E, Thieblemont C. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.39_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Ferrero
- Hematology Division; Università di Torino, Molecular Biotechnologies and Health Sciences; Torino Italy
| | - M. Ladetto
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo; SC Ematologia; Alessandria Italy
| | - K. Beldjord
- Hemato-Oncology; Hôpital Saint-Louis; Paris France
| | - D. Drandi
- Hematology Division; Università di Torino, Molecular Biotechnologies and Health Sciences; Torino Italy
| | - C. Stelitano
- U.O.C. Ematologia; Grande Ospedale Metropolitano Bianchi Melacrino Morelli; Reggio Calabria Italy
| | - S. Bernard
- Hemato-Oncology; Hôpital Saint-Louis; Paris France
| | - B. Castagnari
- UOC of Hematology; Hospital Santa Maria delle Croci; Ravenna Italy
| | | | - M. Cesaretti
- University of Modena and Reggio Emilia; Department of Diagnostic, Clinical and Public Health Medicine; Modena Italy
| | - I. Alvarez
- AUSL Reggio Emilia/IRCCS; Arcispedale Santa Maria Nuova, UOC of Hematology; Reggio Emilia Italy
| | - R. Gressin
- Grenoble Alpes University Hospital; Department of Hematology; Grenoble France
| | - M. Ponzoni
- Pathology Unit; Ateneo Vita-Salute and San Raffaele Scientific Institute; Milano Italy
| | - C. Tripodo
- Department of Health Science; Human Pathology Section,Tumor Immunology Unit, University of Palermo; Palermo Italy
| | | | - L. Baseggio
- Pierre-Benite; Cytology, CHU Lyon; Lyon France
| | - A. Liberati
- University of Perugia; Oncology-Hematology, Santa Maria Hospital; Terni Italy
| | - M. Merli
- ASST Settelaghi; University Hospital Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | | | - C. Patti
- Division of Hematology; Azienda Ospedali Riuniti Villa Sofia-Cervello; Palermo Italy
| | - M. Cabras
- Ospedale Businco; Division of Hematology; Cagliari Italy
| | - P. Feugier
- University Hospital of Nancy; Department of Haematology; Nancy France
| | - S. Pozzi
- Unit of Target Therapy in Onco-Hematology and Osteoncology, University of Modena and Reggio Emilia, Department of Oncology and Hematology; Modena Cancer Center; Modena Italy
| | - E. Zucca
- Institute of Oncology Research; Università della Svizzera Italiana (USI), IOSI, Oncology Institute of Southern Switzerland and IOR; Bellinzona Switzerland
| | - E. Iannitto
- Department of Oncology; “La Maddalena”, Onco-Hematology and BMT Unit; Palermo Italy
| | | |
Collapse
|
38
|
Bruscaggin A, Mollejo M, Tapia G, Gomes da Silva M, Novak U, Dietrich S, Ponzoni M, Rambaldi A, Corradini P, Vitolo U, Merli M, Tzankov A, Cogliatti S, Montalban C, Marasca R, de Leval L, Visco C, Baptista M, Tousseyn T, Facchetti F, Paulli M, Mazzucchelli L, Bea S, Oscier D, Zinzani P, Bhagat G, Inghirami G, Gaidano G, Traverse-Glehen A, Thieblemont C, Piris M, Cavalli F, Arcaini L, Zucca E, Rossi D. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.138_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
39
|
Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018; 32:1799-1803. [PMID: 29572505 PMCID: PMC6087720 DOI: 10.1038/s41375-018-0023-2] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/21/2017] [Accepted: 12/22/2017] [Indexed: 11/23/2022]
Affiliation(s)
- S Rule
- Plymouth University Medical School, Plymouth, UK.
| | - W Jurczak
- Department of Hematology, Jagiellonian University, Krakow, Poland
| | - M Jerkeman
- Skånes University Hospital, Lund University, Lund, Sweden
| | - C Rusconi
- Hematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy
| | - M Trneny
- Ist Dept Medicine, Charles University General Hospital, Prague, Czech Republic
| | - F Offner
- Departement Oncologie, UZ Gent, Ghent, Belgium
| | - D Caballero
- Instituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain
| | - C Joao
- Institutto Português de Oncologia de Lisboa, Portugal and Champalimaud Centre for the Unknown, Hematology, Lisbon, Portugal
| | - M Witzens-Harig
- Klinikum der Ruprechts-Karls-Universität Heidelberg, Med. Klinik u. Poliklinik V, Heidelberg, Germany
| | - G Hess
- Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University, Mainz, Germany
| | | | - S-G Cho
- Seoul St. Mary's Hospital, Seocho-gu, Seoul, South Korea
| | - C Thieblemont
- APHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Paris, France
| | - W Zhou
- Janssen Research & Development, Raritan, NJ, USA
| | - T Henninger
- Janssen Research & Development, Raritan, NJ, USA
| | - J Goldberg
- Janssen Research & Development, Raritan, NJ, USA
| | - J Vermeulen
- Janssen Research & Development, Leiden, The Netherlands
| | - M Dreyling
- Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany
| |
Collapse
|
40
|
Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol 2018. [PMID: 28633365 PMCID: PMC5834070 DOI: 10.1093/annonc/mdx289] [Citation(s) in RCA: 183] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Background Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. Patients and methods This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or aggressive malignant lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis. Results Thirty-three patients with indolent lymphoma and 51 with aggressive lymphoma received copanlisib. Follicular lymphoma (48.5%) and peripheral T-cell lymphoma (33.3%) were the most common histologic subtypes. Most patients (78.6%) had received prior rituximab and 54.8% were rituximab-refractory. Median duration of treatment was 23 and 8 weeks in the indolent and aggressive cohorts, respectively (overall range 2-138). Eighty patients were evaluated for efficacy. The objective response rate was 43.7% (14/32) in the indolent cohort and 27.1% (13/48) in the aggressive cohort; median progression-free survival was 294 days (range 0-874) and 70 days (range 0-897), respectively; median duration of response was 390 days (range 0-825) and 166 days (range 0-786), respectively. Common adverse events included hyperglycemia (57.1%; grade ≥3, 23.8%), hypertension (54.8%; grade ≥3, 40.5%), and diarrhea (40.5%; grade ≥3, 4.8%), all generally manageable. Neutropenia occurred in 28.6% of patients (grade 4, 11.9%). Molecular analyses showed enhanced antitumor activity in tumors with upregulated phosphatidylinositol 3-kinase pathway gene expression. Conclusion Intravenous copanlisib demonstrated promising efficacy and manageable toxicity in heavily pretreated patients with various subtypes of indolent and aggressive malignant lymphoma. Subtype-specific studies of copanlisib in patients with follicular, peripheral T-cell, and mantle cell lymphomas are ongoing. This trial is registered with ClinicalTrials.gov number NCT01660451 (Part A).
Collapse
Affiliation(s)
- M Dreyling
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
| | - F Morschhauser
- Hematology Department, Hôpital Claude Huriez, Unité GRITA, Lille University, Lille
| | - K Bouabdallah
- Department of Hematology and Cellular Therapy, University Hospital of Bordeaux, Pessac, France
| | - D Bron
- Department of Clinical and Experimental Hematology, Jules Bordet Institute (Free University of Brussels - ULB), Brussels, Belgium
| | - D Cunningham
- Department of Clinical and Experimental Haematology, The Royal Marsden Hospital, Sutton, UK
| | - S E Assouline
- Division of Hematology, Jewish General Hospital, Montreal, Canada
| | - G Verhoef
- Department of Haematology, University Hospital Leuven, Leuven, Belgium
| | - K Linton
- Department of Haemato-oncology, The Christie NHS Foundation Trust, Manchester, UK
| | - C Thieblemont
- Department of Hemato-oncology, APHP-Hôpital Saint-Louis, Paris.,Diderot University, Sorbonne Paris Cité, Paris.,EA3788, Descartes University, Paris, France
| | - U Vitolo
- Department of Oncology and Hematology, Città della Salute e della Scienza di Torino, Torino, Italy
| | | | | | | | | | - L Liu
- Bayer HealthCare Pharmaceuticals, Inc., Whippany, USA
| | | | - C Peña
- Bayer HealthCare Pharmaceuticals, Inc., Whippany, USA
| | | | - B H Childs
- Bayer HealthCare Pharmaceuticals, Inc., Whippany, USA
| | - P L Zinzani
- Department of Hematology and Oncology, Policlinico S. Orsola-Malpighi, Bologna, Italy
| |
Collapse
|
41
|
Petrella T, Copie-Bergman C, Brière J, Delarue R, Jardin F, Ruminy P, Thieblemont C, Figeac M, Canioni D, Feugier P, Fabiani B, Leroy K, Parrens M, André M, Haioun C, Salles GA, Gaulard P, Tilly H, Jais JP, Molina TJ. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. Ann Oncol 2018; 28:1042-1049. [PMID: 28327893 DOI: 10.1093/annonc/mdx022] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Background Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the two main biological risk factors in elderly patients treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP), maintain their prognostic value in a large prospective clinical trial. Patients and methods We evaluated 285 paraffin-embedded samples from patients (60-80 years of age) enrolled in the Lymphoma Study Association trial LNH03-6B who were treated with R-CHOP. We correlated the COO defined by the transcriptome according to the Wright algorithm with that defined by the Hans algorithm in a subset of 62 tumors with available frozen tissue samples. Results The non-germinal center B-cell-like phenotype according to the Hans algorithm and BCL2 expression (but not MYC and BCL2 coexpression) predicted worse progression-free survival [hazard ratio (HR)=1.78, P = 0.003 and HR = 1.79, P = 0.003, respectively] and overall survival (HR = 1.85, P = 0.005 and HR = 1.67, P = 0.02, respectively) independently of the International Prognostic Index. The correlation between the Hans algorithm and the Wright algorithm was 91%, with an almost perfect concordance according to a kappa test (0.81). Conclusions Our results suggest that immunohistochemically defined COO remains a useful tool for predicting prognosis in diffuse large B-cell lymphoma when performed under optimized standardized conditions and that BCL2 expression may help to identify elderly patients at risk for relapse and who could potentially respond to anti-BCL2 targeted agents. In this prospective phase III trial, the coexpression of MYC and BCL2 does not appear to predict worse survival. Clinical trial Number NCT00144755.
Collapse
Affiliation(s)
| | - C Copie-Bergman
- Pathology, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil, Créteil and IMRB, INSERM U955 Unité, Créteil
| | - J Brière
- Pathology, AP-HP, Necker, Université Paris Descartes, Sorbonne Paris Cité, Paris
| | - R Delarue
- Hematology, AP-HP, Necker Enfants-Malades, Paris
| | - F Jardin
- Hematology and UMR918, Centre Henri Becquerel, Université de Rouen, Rouen
| | - P Ruminy
- Hematology and UMR918, Centre Henri Becquerel, Université de Rouen, Rouen
| | - C Thieblemont
- Hemato-Oncology, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité and EA 7324, Paris Descartes, Sorbonne Paris Cité, Paris
| | - M Figeac
- Functional Genomic Platform, Cancer Research Institute, Lille
| | - D Canioni
- Pathology, AP-HP, Necker, Université Paris Descartes, Sorbonne Paris Cité, Paris
| | | | - B Fabiani
- Pathology, AP-HP, Saint-Antoine, Paris
| | - K Leroy
- Pathology, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil, Créteil and IMRB, INSERM U955 Unité, Créteil
| | - M Parrens
- Pathology, CHU Bordeaux, Inserm U1053, Bordeaux, France
| | - M André
- Hematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
| | - C Haioun
- Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil, Créteil
| | - G A Salles
- Haematology, Hospices Civils de Lyon, Université Claude Bernard, Pierre Bénite
| | - P Gaulard
- Pathology, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil, Créteil and IMRB, INSERM U955 Unité, Créteil
| | - H Tilly
- Hematology and UMR918, Centre Henri Becquerel, Université de Rouen, Rouen
| | - J P Jais
- Biostatistics, AP-HP, Necker Enfants Malades, Université Paris Descartes, Sorbonne Paris Cité, Paris
| | - T J Molina
- Pathology, AP-HP, Necker, Université Paris Descartes, Sorbonne Paris Cité, Paris.,EA7324, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
42
|
Abstract
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing importance in the treatment of B-cell malignancies. These include inhibitors of Bruton tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), splenic tyrosine kinase and protein kinase Cβ. Two agents are already approved in the USA and Europe: ibrutinib, a BTK inhibitor, for the treatment of chronic lymphatic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia; and idelalisib, a PI3Kδ inhibitor, for the treatment of CLL and follicular lymphoma. In addition, the role of these drugs in diffuse large B-cell lymphoma and marginal zone lymphoma is under investigation, as single agents and in combination with chemotherapy. In CLL, both ibrutinib and idelalisib have an established role as first-line therapy in patients with del(17p), and in MCL, ibrutinib is a standard option for patients relapsing after chemoimmunotherapy. Unexpected toxicities have been encountered when combining these potent new agents with other drugs, including chemotherapy and lenalidomide, and based on this experience the risks and benefits of novel combinations must be evaluated carefully. In this review, we summarize the efficacy and safety results with these inhibitors and discuss novel combinations that are under study and the future role of BCR inhibitors in these disorders.
Collapse
Affiliation(s)
- M Jerkeman
- Department of Oncology, Lund University, Lund, Sweden
| | - M Hallek
- Department of Internal Medicine I, Cologne University Hospital, Cologne, Germany
| | - M Dreyling
- Department of Medicine III, University of Munich, Munich, Germany
| | - C Thieblemont
- Hemato-Oncology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - E Kimby
- Hematology Center, Department of Medicine, Karolinska Institute, Stockholm, Sweden
| | - L Staudt
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
43
|
Reddy NM, Thieblemont C. Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. Ann Oncol 2017; 28:2680-2690. [PMID: 29045503 DOI: 10.1093/annonc/mdx358] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Maintenance therapy has proven efficacy in indolent non-Hodgkin lymphoma (NHL), yet its role in diffuse large B-cell lymphoma (DLBCL) is an area of ongoing investigation. While DLBCL is potentially curable, >30% of patients relapse following front-line therapy and have a poor prognosis, especially those with refractory disease. Maintenance therapy holds promise to maintain response post-induction. PATIENTS AND METHODS Keyword searches were carried out in PubMed and congress abstracts of 'diffuse large B-cell lymphoma' and 'maintenance' and focused on phase II/III studies of maintenance following front-line induction. RESULTS Although used in indolent forms of NHL, studies of maintenance therapy with rituximab in patients with DLBCL responding to front-line R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) have not improved efficacy and are not recommended. Targeted agents enzastaurin and everolimus reported results from the phase III studies PRELUDE and PILLAR-2, respectively, both of which showed no proven maintenance benefit following front-line chemoimmunotherapy induction. Overall, the reported efficacy results with these agents in the maintenance setting do not outweigh the risks. Lenalidomide for maintenance has been reported in three studies. Results from two phase II trials on lenalidomide maintenance revealed positive outcomes in higher-risk patients following induction, resulting in improved progression-free survival in relapsed DLBCL patients who were ineligible for transplantation. First analysis from the phase III REMARC trial showed a significant improvement in progression-free survival for lenalidomide versus placebo, with no difference in overall survival, following front-line R-CHOP induction in elderly patients. CONCLUSIONS Based on currently available studies of DLBCL maintenance therapies, initial results in front-line, as well as the relapsed setting, with immunomodulators such as lenalidomide show promise for further research to identify appropriate patients who would most benefit. Overall, this review of maintenance studies underscores the need for additional analyses of patient subtypes, clinical risk status, and molecular profiles, with careful consideration of study end points.
Collapse
Affiliation(s)
- N M Reddy
- Department of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, USA;.
| | - C Thieblemont
- Department of Hemato-Oncology, Hôpital Saint-Louis, Paris, France.
| |
Collapse
|
44
|
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28:1436-1447. [PMID: 28379322 PMCID: PMC5834038 DOI: 10.1093/annonc/mdx097] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Collapse
Affiliation(s)
| | - P. Hilden
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B. Coiffier
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - A. Hagenbeek
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - G. Salles
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - W. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA
| | - J. F. Seymour
- Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - K. Kelly
- Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, London, UK
| | - M. Pfreunschuh
- Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany
| | - F. Morschhauser
- Department of Hematology, Université de Lille 2, Lille, France
| | - H. Schoder
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | | | - J. Rademaker
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | - R. Advani
- Department of Oncology, Stanford University, Stanford
| | | | | | | | - L. H. Sehn
- British Columbia Cancer Agency, Vancouver, Canada
| | - A. Engert
- Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - P.-L. Zinzani
- Department of Hematology, University of Bologna, Bologna
| | - M. Federico
- Department of Diagnostic Medicine, University of Modena, Modena, Italy
| | - M. Hutchings
- Department of Hematology, University of Copenhagen, Denmark
| | - C. Bollard
- Children’s National Health System, Washington, USA
| | - M. Trneny
- Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic
| | | | - K. Tobinai
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J. S. Abramson
- Massachusetts General Hospital, Center for Lymphoma, Boston
| | - N. Fowler
- U.T. M.D.Anderson Cancer Center, Houston
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - M. Smith
- Cleveland Clinic, Cleveland, USA
| | | | - J. Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M. Dreyling
- Medicine Clinic III, Ludwig Maximilian University, Munich, Germany
| | | | - R. F. Little
- Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - I. Aurer
- Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - A. Gopal
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - S. Rule
- Haematology Department, Plymouth University, UK
| | | | - I. Kloos
- Servier, Neuilly sur Seine, France
| | - M. S. Kaminski
- University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - M. Meignan
- Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - L. H. Schwartz
- Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
| | - J. P. Leonard
- Weill Cornell Medicine and and New York Presbyterian Hospital, New York
| | - S. J. Schuster
- University of Pennsylvania School of Medicine, Philadelphia, USA
| | - V. E. Seshan
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
45
|
Zinzani P, Thieblemont C, Melnichenko V, Osmanov D, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Caballero Barrigón M, Christian B, Gulbas Z, Özcan M, Salles G, Shipp M, Balakumaran A, Chlosta S, Chatterjee A, Armand P. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_49] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | | | - V. Melnichenko
- Hematology; The National Medical Surgical Сentre named after N.I. Pirogov, Moscow; Russian Federation
| | - D. Osmanov
- Russian Academy of Medical Sciences; N.N. Blokhin Russian Oncological Research Center; Moscow Russian Federation
| | - K. Bouabdallah
- Hematology and Cell Therapy; Groupe Hospitalier du Haut Leveque; Pessac France
| | - J. Walewski
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warsaw Poland
| | - A. Majlis
- Hematology, University of Chile; Hospital del Salvador; Santiago Chile
| | - L. Fogliatto
- Hematology; Hospital de Clinicas de Porto Alegre; Porto Alegre Brazil
| | | | - B. Christian
- Division of Hematology; Ohio State University - James Comprehensive Cancer Center; Columbus USA
| | - Z. Gulbas
- Hematologic Oncology; Anadolu Medical Center; Gebze Turkey
| | - M. Özcan
- Division of Hematology; Ankara University School of Medicine; Ankara Turkey
| | - G.A. Salles
- Hospices Civils de Lyon, Cancer Research Center of Lyon; Claude Bernard University Lyon; Pierre Benite France
| | - M.A. Shipp
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| | | | - S. Chlosta
- Clinical Research; Merck & Co., Inc.; Kenilworth USA
| | - A. Chatterjee
- Clinical Research; Merck & Co., Inc.; Kenilworth USA
| | - P. Armand
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| |
Collapse
|
46
|
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker L, Salles G, Tilly H, Lamy T, Gressin R, Hermine O. Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_74] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | - C. Thieblemont
- Hemato-Oncologie, APHP, Hôpital Saint-Louis; Paris France
| | - L. Oberic
- Hématologie, IUCT Oncopole; Toulouse France
| | - A. Moreau
- Hématologie, CHU De Nantes; Nantes France
| | | | | | - G. Damaj
- Hématologie, CHU Caen; Caen France
| | | | | | | | | | | | - C. Haioun
- hématologie, CHU Creteil; Creteil France
| | | | | | - O. Tournilhac
- Hématologie, CHU Clermont-Ferrand; Clermont-Ferrand France
| | - K. Le Dû
- Hématologie, Clinique Victor Hugo; Le Mans France
| | | | - G. Cartron
- hématologie, CHU Montpellier; Montpellier France
| | | | - G. Salles
- Hématologie, AP-HL Lyon; Lyon France
| | - H. Tilly
- hématologie, Centre Becquerel; Rouen France
| | - T. Lamy
- Hématologie, CHU Rennes; Rennes France
| | - R. Gressin
- Hématologie, CHU Grenoble; Grenoble France
| | - O. Hermine
- Hématologie, AP-HP Necker Paris; Paris France
| |
Collapse
|
47
|
Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho S, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_133] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S. Rule
- Haematology; Derriford Hospital; Plymouth UK
| | - W. Jurczak
- Hematology; Jagiellonian University; Krakow Poland
| | - M. Jerkeman
- Oncology; Skånes University Hospital; Lund Sweden
| | - R. Santucci Silva
- Oncology; Instituto de Ensino e Pesquisa Sao Lucas; Sao Paulo Brazil
| | - C. Rusconi
- Hematology and Oncology; Niguarda Hospital; Milan Italy
| | - M. Trneny
- First Department Medicine; Charles University General Hospital; Prague Czech Republic
| | | | - D. Caballero
- Hematology; Hospital Clinico Universitario Salamanca; Salamanca Spain
| | - C. Joao
- Oncology; Institutto Português de Oncologia de Lisboa; Lisbon Portugal
| | | | - G. Hess
- Hematology, Oncology and Pneumology; University Medical School of the Johannes Gutenberg University; Mainz Germany
| | | | - S. Cho
- Hematology; Seoul St. Mary's Hospital; Seoul Republic of Korea
| | | | - W. Zhou
- Oncology; Janssen Research & Development; Raritan USA
| | - T. Henninger
- Oncology; Janssen Research & Development; Raritan USA
| | - J.D. Goldberg
- Oncology; Janssen Research & Development; Raritan USA
| | - J. Vermeulen
- Oncology; Janssen Research & Development; Beerse Belgium
| | - M. Dreyling
- Medicine III; Klinikum der Universität München, LMU; Munich Germany
| |
Collapse
|
48
|
Casasnovas R, Westin J, Thieblemont C, Zijlstra J, Hill B, De La Cruz Vicente F, Choquet S, Caimi P, Kaplan J, Canales M, Kuruvilla J, Follows G, van den Neste E, Meade J, Wrigley B, Devlin M, Saint-Martin J, Nippgen C, Gardner H, Shacham S, Kauffman M, Maerevoet M. A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - J. Westin
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - C. Thieblemont
- APHP, Hemato-Oncology; Hopital Saint-Louis; Paris France
| | - J. Zijlstra
- Lunenburg Lymphoma Phase-I Consortium; VU University Medical Center; Amsterdam The Netherlands
| | - B. Hill
- Taussig Cancer Institute; Cleveland Clinic; Cleveland USA
| | | | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - P. Caimi
- Seidman Cancer Center; University Hospital; Cleveland USA
| | - J. Kaplan
- Feinberg School of Medicine; Northwestern University; Chicago USA
| | - M. Canales
- Hematology; Hospital Universitario La Paz; Madrid Spain
| | - J. Kuruvilla
- Hematology; Princess Margaret Hospital; Toronto Canada
| | - G. Follows
- NHS Foundation Trust; Cambridge University Teaching Hospitals; Cambridge UK
| | - E. van den Neste
- Hematology; Cliniques Universitaires UCL Saint-Luc; Brussels Belgium
| | - J. Meade
- Clinical, Karyopharm Therapeutics; Newton USA
| | - B. Wrigley
- Clinical, Karyopharm Therapeutics; Newton USA
| | - M. Devlin
- Clinical, Karyopharm Therapeutics; Newton USA
| | | | - C. Nippgen
- Clinical, Karyopharm Therapeutics; Newton USA
| | - H. Gardner
- Clinical, Karyopharm Therapeutics; Newton USA
| | - S. Shacham
- Clinical, Karyopharm Therapeutics; Newton USA
| | - M. Kauffman
- Clinical, Karyopharm Therapeutics; Newton USA
| | - M. Maerevoet
- Hematology; Institute Jules Bordet; Brussels Belgium
| |
Collapse
|
49
|
Delfau-Larue M, Beldi-Ferchiou A, Jais J, Godard N, Salles G, Casasnovas R, Tilly H, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Perrot A, Sebban C, Bouabdallah R, Gonzalez H, Corront B, Oberic L, Briere J, Gaulard P, Coiffier B, Thieblemont C. LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: a LYSA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M.H. Delfau-Larue
- Biological Hematology and Immunology department, APHP, Groupe Hospitalier Mondor, INSERM U 955; Creteil France
| | - A. Beldi-Ferchiou
- Biological Hematology and Immunology department, APHP, Groupe Hospitalier Mondor, INSERM U 955; Creteil France
| | - J. Jais
- Biostatistics Unit, APHP; Univ Paris Descartes; Paris France
| | - N. Godard
- Biological Hematology and Immunology department, APHP, Groupe Hospitalier Mondor, INSERM U 955; Creteil France
| | - G.A. Salles
- Hematology; Centre Hospitalier Lyon Sud; Pierre-Benite France
| | - R. Casasnovas
- Hematology; CHU Dijon - Hopital du Bocage; Dijon France
| | - H. Tilly
- INSERM U918; Centre Henri Becquerel; Rouen France
| | - C. Fruchart
- Institut d'Hématologie de Basse Normandie; CHU Caen; Caen France
| | | | - C. Haioun
- Lymphoid Malignancies Unit, APHP, Groupe Hospitalier Mondor; Creteil France
| | - J. Lazarovici
- Clinical Hematology, Gustave Roussy Cancer Center; Villejuif France
| | - A. Perrot
- Hematology department, CHU Brabois; Vandoeuvre les Nancy France
| | - C. Sebban
- Onco Hematology; Centre Leon Berard; Lyon France
| | - R. Bouabdallah
- Onco Hematology; Institut Paoli Calmettes; Marseille France
| | | | - B. Corront
- Hematology; CH Annecy Genevois, Epagny Metz-Tessy; France
| | - L. Oberic
- Hematology; IUC - Oncopole CHU Toulouse; Toulouse France
| | - J. Briere
- Pathology; APHP, Hopital Saint-Louis; Paris France
| | - P. Gaulard
- Pathology; APHP, Hopital Henri Mondor; Creteil France
| | - B. Coiffier
- CNRS UMR5239; Centre Hospitalier Lyon Sud; Pierre Benite France
| | - C. Thieblemont
- Hemato-Oncology, APHP; Hopital Saint-Louis; Paris France
| |
Collapse
|
50
|
Collins G, Noy A, de Vos S, Thieblemont C, Martin P, Flowers C, Morschhauser F, Ma S, Coleman M, Peles S, Smith S, Barrientos J, Smith A, Munneke B, Dimery I, Beaupre D, Chen R. Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open-label, phase 2 study. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_76] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- G.P. Collins
- Department of Haematology; Oxford University Hospitals NHS Foundation Trust; Oxford UK
| | - A. Noy
- Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - S. de Vos
- Division of Hematology/Oncology; David Geffen School of Medicine at UCLA; Los Angeles USA
| | - C. Thieblemont
- APHP; Hopital Saint-Louis-Paris Diderot University, Hemato-oncology Department; Paris France
| | - P. Martin
- Division of Hematology/Oncology; Weill Cornell Medical College; New York USA
| | - C. Flowers
- Department of Hematology and Medical Oncology; Winship Cancer Institute of Emory University; Atlanta USA
| | - F. Morschhauser
- Hematologie; Centre Hospitalier Universitaire, Université de Lille, EA GRIIOT; Lille Cedex France
| | - S. Ma
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine; Northwestern University; Chicago USA
| | - M. Coleman
- Division of Hematology and Medical Oncology, Center for Lymphoma and Myeloma; New York-Presbyterian Hospital and Weill Medical College; New York USA
| | - S. Peles
- Hematology; Florida Cancer Specialists; Atlantis USA
| | - S. Smith
- Department of Medicine and Clinical Research Division, Division of Medical Oncology; University of Washington and Fred Hutchinson Cancer Research Center; Seattle USA
| | - J. Barrientos
- Clinical Research Division, Fred Hutchinson Cancer Research Center; Hempstead USA
| | - A. Smith
- Clinical Operations, Pharmacylics LLC, an Abbvie Company; Sunnyvale USA
| | - B. Munneke
- Biostatistics; Pharmacylics LLC, an Abbvie Company; Sunnyvale USA
| | - I. Dimery
- Clinical Operations, Pharmacylics LLC, an Abbvie Company; Sunnyvale USA
| | - D. Beaupre
- Clinical Operations, Pharmacylics LLC, an Abbvie Company; Sunnyvale USA
| | - R. Chen
- Hematology/Oncology; City of Hope National Medical Center; Duarte USA
| |
Collapse
|